Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Contributor

CEO G. Steven Burrill

<p> G. Steven Burrill is CEO of Burrill &amp; Company, a San Francisco-based life science merchant bank with over $500 million under management. In 2002, Burrill was recognized as a biotech investment visionary by <em>Scientific American</em>. He currently serves as chairman of the boards of Icoria, Pharmasset, and Pyxis Genomics and is a member of the boards of Catalyst Biosciences, DepoMed, Galapagos Genomics, Targacept, and Third Wave Technologies. Prior to founding Burrill &amp; Company in 1994, he spent 28 years with Ernst &amp; Young, directing and coordinating the firm&#39;s services to clients in the biotechnology/life sciences/high technology/manufacturing industries worldwide.</p>

More GEN Content From This Contributor:

GEN Articles

More GEN Content From This Contributor:

GEN Podcasts

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »